---
title: "Docetaxel Followed by Provenge in Metastatic Prostate Cancer"
description: "This clinical study will evaluate the role of combination therapy of docetaxel followed by Provenge for patients with metastatic castration-resistant prost"
url: "https://www.clareohealth.com/clinical-trials/NCT02793765"
---

This clinical study will evaluate the role of combination therapy of docetaxel followed by Provenge for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or surgical treatments that lower testosterone). The purpose of this study is to look at the combination therapy of docetaxel followed by Provenge to correlate the immunological biomarkers with clinical results for therapy. Biomarkers are genes, proteins and other molecules that affect how cancer cells grow, multiply, die and respond to other compounds in the body. The study drugs are approved by the Food and Drug Administration (FDA). Treatment will be administered on an outpatient basis. Patients will receive 6 cycles of docetaxel followed by Provenge. Docetaxel is an antineoplastic (chemotherapy that affects cancer cell growth) agent. Docetaxel dose of 75 mg/m2 will be given intravenously as a 1-hour infusion every 21 days on Day 1 for 6 cycles. Provenge is an immunotherapy (vaccine made from patient's own blood cells) that reprograms immune cells to attack cancer. A course of therapy consists of three doses of Provenge administered at 2-week intervals. The strategy aims to determine whether cytokine production and T cell infiltration of tumor cells could favor regression using a combination of chemotherapy plus vaccine. Tissue endpoints will include biopsies prior to first chemotherapy and first vaccine therapy and at the end of each therapy. Prostate cancer tissue infiltrates will be studied for expression of CD3, CD4, CD8, CD25/FOX3P, CD56, CTLA-4, PD-1, and Ki67. Additional immunological endpoints will be secondary antigen spread and various cytokine biomarkers.

## Key Facts

**ID:** NCT02793765
**Status:** WITHDRAWN
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 0
**Sponsor:** The University of Texas Health Science Center, Houston

## About This Study

This clinical trial is testing a combination of docetaxel, a chemotherapy drug, followed by Provenge, an immunotherapy vaccine, for men with metastatic castration-resistant prostate cancer (a type of prostate cancer that continues to grow despite treatments that lower testosterone). The goal is to see how this combination affects cancer progression and immune response.

## Conditions

- Prostate Cancer

## Interventions

**DRUG: Docetaxel**


**BIOLOGICAL: Sipuleucel-T**


## Eligibility

Inclusion Criteria: * Male 18 years and older. * Pathologic confirmation of prostate adenocarcinoma. * Asymptomatic or minimally symptomatic disease.

## Who Can Participate

**Minimum age:** 18

**Sex:** MALE

**Accepts healthy volunteers:** No

## Study Locations

- UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States

## Contact Information

## Important Dates

**Study start:** December 1, 2016

**Completion date:** July 1, 2021

**Last updated:** October 30, 2017

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have metastatic prostate cancer that is resistant to hormone treatments.
- Your cancer has progressed despite previous treatments.
- You are looking for new treatment options that combine chemotherapy and immunotherapy.
- You are interested in participating in a study that monitors immune responses to treatment.

### Questions to Ask

- Am I eligible for this trial based on my current health and treatment history?
- How does the combination of docetaxel and Provenge compare to other treatments I might consider?
- What are the potential side effects of docetaxel and Provenge?
- How often will I need to visit the clinic for treatment and monitoring?
- What kind of tests will be done to monitor my progress during the trial?
- What happens if I experience side effects or my cancer progresses during the trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02793765)
